Skip to content

uniQure QURE Free cash flow

Free cash flow at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$198M-18.6%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$133.67M+2.1%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$60.24M-107%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$109.4M-102%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$62.75M+7.3%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's free cash flow?
uniQure (QURE) reported free cash flow of -$38.38M in Q1 2026.
How has uniQure's free cash flow changed year-over-year?
uniQure's free cash flow increased by 13.2% year-over-year, from -$44.23M to -$38.38M.
What is the long-term trend for uniQure's free cash flow?
Over 2 years (2022 to 2025), uniQure's free cash flow has grown at a 4.7% compound annual growth rate (CAGR), from -$162.75M to -$178.4M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.